Irbesartan And Hydrochlorothiazide Teva 7239 3 Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
Irbesartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. Irbesartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy. Irbesartan and hydrochlorothiazide tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and.
What should I know before taking it?
Irbesartan and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product.Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.Do not coadminister aliskiren with irbesartan and hydrochlorothiazide tablets in patients with diabetes [see Drug Interactions (7)].
What important warnings are listed?
When pregnancy is detected, discontinue irbesartan and hydrochlorothiazide tablets as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ].
How is this medication usually taken?
Irbesartan and hydrochlorothiazide tablets USP, 150 mg/12.5 mg and 300 mg/12.5 mg are Peach coloured mottled, oval shaped, biconvex, uncoated tablets. 150 mg/12.5 mg debossed with “L180” on one side and plain on other side and 300 mg/12.5 mg debossed with “L181” on one side and plain on other side. Irbesartan and hydrochlorothiazide tablets USP, 300 mg/25 mg is Pinkish brown, oval shaped, biconvex, film coated tablets, debossed with “L182” on one side and plain on other side.
What side effects are listed?
Most common adverse events (≥5% on irbesartan and hydrochlorothiazide tablets and more often than on placebo) are dizziness, fatigue, and musculoskeletal pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
What interactions are listed?
NSAIDs and selective COX-2 inhibitors: Can reduce diuretic, natriuretic of diuretic, may lead to increased risk of renal impairment and reduced antihypertensive effect. Monitor renal function periodically. (7) • Dual blockade of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (7) • Cholestyramine and colestipol: Reduced absorption of thiazides (7) • Lithium: Increases in serum lithium concentrations and lithium toxicity (7) • Carbamazepine: Increased risk of hyponatremia. (7)
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e842fa14-b18e-4463-9bf1-a1c8700fe33c
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.